Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates

分组1 - Coherus Oncology reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, marking an earnings surprise of -9.68% [1] - The company generated revenues of $12.75 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.86%, and a significant decline from $54.14 million in the same quarter last year [2] - Over the last four quarters, Coherus has not surpassed consensus EPS estimates and has only topped revenue estimates once [2] 分组2 - Coherus Oncology shares have increased by approximately 28.2% since the beginning of the year, contrasting with a 1.5% decline in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.27 on revenues of $14.68 million, and for the current fiscal year, it is -$0.50 on revenues of $96.24 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Coherus belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The trend of estimate revisions for Coherus was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6]